Dr. Jim Wu is founder and CEO of Ark Biosciences. Dr. Wu has an extensive and successful pharma experience in which he contributed to development of antiviral, oncology, metabolic and CNS drugs, including Potiga™/Trobalt™ and Zurampic™ that were approved by FDA and EMEA for global marketing. He was a senior scientist at Schering-Plough Research Institute, now part of Merck, and director of preclinical and translational research at Valeant Pharmaceuticals. He was a founding scientist of Ribapharm that went for IPO at NYSE in 2002 for $800 million USD. More recently he was a member of China management team and head of biology at Roche R&D Center China, where he held responsibility for oncology, virology and diabetic drug discovery. Dr. Wu was CEO of Sumo Bioscience, a California-based biotech startup before he founded Ark Biosciences in 2013, focusing on antiviral drug discovery and clinical development.
Dr. Wu obtained his BSc from University of Science and Technology of China, his PhD from Brown University, and conducted postdoctoral research at Harvard Medical School. He is a coauthor of 60s scientific papers and serves in editorial advisory board of “Antimicrobial Agent and Chemotherapy”. He is also an adjunct professor at Fudan University School of Pharmacy and Shanghai Medical College. In his pharma industrial career, he is a co-inventor of 15 patents and contributed to 6 INDs and 2 NDAs.
Dr Toovey is an infectious disease physician and KOL, with decades of experience in the pharma industry and in drug development. He has authored over 120 scientific publications and contributed to a number of text books. He is a frequent speaker at international conferences, including in the respiratory virus field. Dr Toovey has worked in industry and academia, in both developed and developing countries.
He has taught at the Royal Free and University College Medical School in London, United Kingdom, Academic Centre for Travel Medicine and Vaccines, World Health Organization Collaborating Center, and is associate editor of the journal Travel Medicine and Infectious Disease. He has been an advisor to the World Health Organization (WHO) as well as an External Expert on Influenza to WHO. Dr Toovey graduated as physician from the University of Witwatersrand in South Africa, and obtained a PhD from Ghent University in Ghent, Belgium.
Haiqing Yuan, Ph.D. Dr. Yuan brings over 17 years of management and technical leadership experience in pre-clinical drug research in global pharmaceutical industry. He was previously Senior Director of WuXi AppTec, responsible for discovery chemistry collaborations with multiple pharma and institutional customers. Prior to WuXi, Dr. Yuan held various positions of increasing responsibility at Allergan since 2000, most recently as Research Investigator/Director of Medicinal Chemistry, where he led the drug discover and delivery program, contributed several PCC molecules in the area of metabolic disease and inflammation. He is an inventor of over 30 granted patents and has authored 12 peer reviewed journal articles and book chapters.
Dr. Yuan graduated from Fudan University in China and obtained his Ph.D. from Virginia Tech in the US.